| Case Name | Drug | Patent No(s). | Publicly Available Terms |
|---|---|---|---|
| AstraZeneca AB v. Mylan Pharms. Inc., 17-1778 (Fed. Cir.) | Onglyza® (saxagliptin HCl tablets)
Kombiglyze XR™ (saxagliptin HCl / metformin HCl extended-release tablets) |
RE44,186 | The Federal Circuit granted a joint motion by the parties to voluntarily drop the appeal with each side bearing its own fees and costs.
The district court concluded that patent-in-suit claims were non-obviousness. |
Related Attorneys
Partner
